Use of aminolevulinic acid and derivatives thereof

ABSTRACT

The invention provides the use of a photosensitiser which is 5-aminolevulinic acid (5-ALA) or a derivative (e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and wherein side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm 2  (e.g. 5 to 40 mW/cm 2 ), (iv) said photoactivation is carried out with sunlight. Preferably, side-effects of PDT are prevented or reduced by using (iii) or (iv) in combination with (i) and/or (ii).

This invention relates to photodynamic therapy (PDT), and in particularto the use of 5-aminolevulinic acid (5-ALA) and derivatives of 5-ALA inPDT wherein the side-effects (e.g. pain and/or erythema) of PDT areprevented or reduced.

PDT, or photochemotherapy as it is also known, is a technique for thetreatment of various abnormalities or disorders of the skin or otherepithelial organs or mucosa, especially cancers or pre-cancerouslesions, as well as certain non-malignant lesions (e.g. skin complaintssuch as psoriasis, actinic keratoses (AK) and acne). PDT involves theapplication of photosensitizing (photochemotherapeutic) agents to theaffected area of the body, followed by exposure to photoactivating lightin order to activate the photosensitizing agents and convert them intocytotoxic form, whereby the affected cells are killed or theirproliferative potential diminished.

A range of photosensitizing agents are known, including the psoralens,the porphyrins (e.g. Photofrin®), the chlorins and the phthalocyanins.Amongst the most clinically useful photosensitizing agents known in theart, however, are 5-aminolevulinic acid and its derivatives, for exampleesters such as 5-ALA esters.

Although PDT with 5-ALA and 5-ALA derivatives is clinically useful inthe treatment of a wide range of diseases, a major draw back of suchtreatment is the concomitant side-effects, particularly at the treatmentsite. These often include pain, erythema, swelling, edema, burning,itching, exfoliation, hyperpigmentation and prolonged irritation andhypersensitivity after treatment. Such side-effects are particularlyundesirable when the treatment site is the face, scalp or neck. This isfrequently the case when the PDT is for the treatment of lesions. (e.g.acne, basal cell carcinoma, actinic keratosis, squamous cell carcinoma).

The occurrence of such side effects is recognised in WO2006/051269 whichdiscloses use of 5-ALA esters in PDT for the treatment of acne.WO2006/051269 describes a study wherein a cream comprising 16% wt methylALA ester is applied to the faces of subjects for 3 hours followed byexposure of the subjects' faces to non-coherent red light (light dose 37Jcm⁻²). The treatment was then repeated 2 weeks later. Although theresults confirmed that PDT with methyl ALA ester is effective in thetreatment of acne, the subjects also indicated that the treatment causedsome pain.

WO02/13788 discloses a similar study on use of ALA acid in PDT for thetreatment of acne. In this case 20% ALA acid was applied to the backs ofthe subjects for 3 hours and then the subjects were exposed to 150 J/cm²broad band light. Again the results confirmed that PDT with ALA iseffective for the treatment of acne, but the subjects also reported aplethora of undesirable side effects. For example, WO02/13788 reportsthat erythema, hyperpigmentation and exfoliation were often seen afterPDT treatment and states that in some cases a subsequent treatment evenhad to be postponed. Reports of pain, burning and itching during andafter treatment were also common.

WO02/13788 describes the above-described treatment regime as a “highdose, high energy” regime and it is said to provide a permanentimprovement to acne. WO02/13788 additionally discloses a “low dose, lowenergy” regime that is said to be designed to provide relief from acne.In this treatment 0.1 to 10% wt ALA acid is applied, and after waitingfor the ALA acid to penetrate the skin, is followed by irradiation witha light dose of 1 to 20 J/cm². WO02/13788 suggests that this regime beused in occasional multiple treatments to alleviate acne and be repeatedas necessary to maintain diminishment thereof. Although it is recognisedthat use of such a regime may be pain free, the implication inWO02/13788 is that the therapeutic effect of this treatment regime isless than the high dose, high energy regime it describes andexemplifies.

A need still therefore exists for alternative PDT methods that are freefrom undesirable side effects (e.g. pain) but which have hightherapeutic efficacy.

It has now surprisingly been found that substantially pain free (e.g.pain free), therapeutically acceptable, PDT can be achieved by modifyingthe photosensitiser-composition used in the PDT and/or altering the PDTprocedure.

Thus viewed from a first aspect the invention provides the use of aphotosensitiser which is 5-aminolevulinic acid (5-ALA) or a derivative(e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof,in the manufacture of a composition for use in photodynamic therapy(PDT) on an animal, wherein said PDT comprises:

-   -   (a) administering to said animal a composition comprising said        photosensitiser; and    -   (b) photoactivating said photosensitiser, and side-effects (e.g.        pain and/or erythema) of said PDT are prevented or reduced by        use of one or more of (i)-(iv):    -   (i) said composition comprises said photosensitiser in a        concentration of less than 10% wt (e.g. 0.5 to 8% wt),    -   (ii) said composition is administered for less than 2 hours        (e.g. 30 minutes to 90 minutes) prior to said photoactivation,    -   (iii) said photoactivation is carried out with a light source        having a fluence rate of less than 50 mW/cm² (e.g. 5 to 40        mW/cm²),    -   (iv) said photoactivation is carried out with sunlight.

Viewed from a further aspect, the invention provides a method ofpreventing or reducing side-effects (e.g. pain and/or erythema) ofphotodynamic therapy (PDT) in an animal, wherein said PDT comprises:

-   -   (a) administering to said animal a composition comprising a        photosensitiser as hereinbefore defined; and    -   (b) photoactivating said photosensitiser, and side-effects of        said PDT are prevented or reduced by use of one or more of        (i)-(iv):    -   (i) said composition comprises said photosensitiser in a        concentration of less than 10% wt (e.g. 0.5 to 8% wt),    -   (ii) said composition is administered for less than 2 hours        (e.g. 30 minutes to 90 minutes) prior to said photoactivation,    -   (iii) said photoactivation is carried out with a light source        having a fluence rate of less than 50 mW/cm² (e.g. 5 to 40        mW/cm²),    -   (iv) said photoactivation is carried out with sunlight.

In a particularly preferred aspect of the invention, side-effects of PDTare prevented or reduced by use of (iii) or (iv) in combination with oneor both of (i) and (ii).

In preferred uses and methods of the invention, the PDT hassubstantially the same therapeutic effect as the corresponding standardPDT treatment.

By the term “animal” is meant herein any human or non-human being.Preferred animals for treatment in accordance with the invention arehumans.

The use of 5-ALA and derivatives of 5-ALA (5-amino-4-oxo-pentanoic acid,otherwise known as 5-aminolevulinic acid) in PDT is well known in thescientific and patent literature (see, for example, J. C. Kennedy etal., J. Clin. Laser Med. Surg. (1996) 14: 289-304, U.S. Pat. No.5,079,262, U.S. Pat. No. 5,211,938, U.S. Pat. No. 5,234,940, U.S. Pat.No. 5,422,093, U.S. Pat. No. 6,034,267, WO91/01727, WO96/28412,WO2005/092838 and WO2006/051269, the contents of which are incorporatedherein by reference). 5-ALA and all such derivatives of 5-ALA, as wellas their pharmaceutically acceptable salts, are suitable for the usesand methods herein described.

The 5-ALA derivatives useful in accordance with the invention maybe anyderivative of 5-ALA capable of forming protoporphyrin IX (PpIX) or anyother photosensitiser (e.g. a PpIX derivative) in vivo. Typically, suchderivatives will be a precursor of PpIX or of a PpIX derivative (e.g. aPpIX ester) in the biosynthetic pathway for haem and which are thereforecapable of inducing an accumulation of PpIX at the site to be treatedfollowing administration in vivo. Suitable precursors of PpIX or PpIXderivatives include 5-ALA prodrugs which might be able to form 5-ALA invivo as an intermediate in the biosynthesis of PpIX or which may beconverted (e.g. enzymatically) to porphyrins without forming 5-ALA as anintermediate. 5-ALA esters are among the preferred compounds for use inthe methods herein described.

Esters of 5-aminolevulinic acid and N-substituted derivatives thereofare preferred photosensitisers for use in the invention. Those compoundsin which the 5-amino group is unsubstituted (i.e. the ALA esters) areparticularly preferred. Such compounds are generally known and describedin the literature (see, for example, WO96/28412, WO02/10120 andWO2005/092838 to PhotoCure ASA, the contents of which are incorporatedherein by reference).

Esters of 5-aminolevulinic acid with substituted or unsubstitutedalkanols, i.e. alkyl esters are especially preferred photosensitisersfor use in the invention. Examples of such compounds include those ofgeneral formula I:

R² ₂N—CH₂COCH₂—CH₂CO—OR¹  (I)

(wherein R¹ represents a substituted or unsubstituted straight-chained,branched or cyclic alkyl group (e.g. a substituted or unsubstitutedstraight-chained alkyl group); and each R² independently represents ahydrogen atom or an optionally substituted alkyl group, e.g. a group R¹)and pharmaceutically acceptable salts thereof.

As used herein, the term “alkyl”, unless stated otherwise, includes anylong or short chain, cyclic, straight-chained or branched aliphaticsaturated or unsaturated hydrocarbon group. The unsaturated alkyl groupsmay be mono- or polyunsaturated and include both alkenyl and alkynylgroups. Unless stated otherwise, such groups may contain up to 40 atoms.However, alkyl groups containing up to 30, preferably up to 10,particularly preferably up to 8, especially preferably up to 6, e.g. upto 4 carbon atoms are preferred.

The substituted alkyl R¹ and R² groups may be mono or poly-substituted.Suitable substituents may be selected from hydroxy, alkoxy, acyloxy,alkoxycarbonyloxy, amino, aryl, nitro, oxo, fluoro, —SR₃, —NR³ ₂ and—PR³ ₂ groups, and each alkyl group may be optionally interrupted by oneor more —O—, —NR₃—, —S— or —PR₃— groups, in which R³ is a hydrogen atomor a C₁₋₆ alkyl group).

Preferred substituted alkyl R¹ groups include those carrying one or moreoxo groups, preferably straight-chained C₄₋₁₂ alkyl (e.g. C₈₋₁₀ alkyl)groups substituted by one, two or three (preferably two or three) oxogroups. Examples of such groups include 3,6-dioxa-1-octyl and3,6,9-trioxa-1-decyl groups.

Particularly preferred for use in the invention are those compounds offormula I in which at least one R² represents a hydrogen atom. Inespecially preferred compounds each R² represents a hydrogen atom.

Compounds of formula I in which R¹ represents an unsubstituted alkylgroup (preferably C₁₋₈ alkyl, e.g. C₁₋₆ alkyl) or an alkyl group (e.g.C₁₋₂ alkyl, especially C₁ alkyl) substituted by a substituent ashereinbefore defined (e.g. by an aryl group such as phenyl or by analkoxy group such as methoxy) are also preferred.

Unsubstituted alkyl groups which may be used in the invention includeboth branched and straight-chained hydrocarbon groups. Compounds offormula I in which R¹ is a C₄₋₈ preferably a C₅₋₈, straight chain alkylgroup which is branched by one or more C₁₋₆ (e.g. C₁₋₂ alkyl) groups arepreferred. Representative examples of suitable unsubstituted branchedalkyl groups include 2-methylpentyl, 4-methylpentyl, 1-ethylbutyl and3,3-dimethyl-1-butyl. 4-methylpentyl is particularly preferred.

Compounds of formula I in which R¹ is a C₁₋₁₀ straight-chained alkylgroup are also preferred. Representative examples of suitableunsubstituted alkyl groups include methyl, ethyl, propyl, butyl, pentyl,hexyl and octyl (e.g. n-propyl, n-butyl, n-pentyl, n-hexyl and n-octyl).Hexyl, especially n-hexyl, is a particularly preferred group. Methyl isalso particularly preferred.

Also preferred for use in the invention are those compounds of formula Iin which R¹ represents a C₁₋₂ alkyl group (preferably a C₁ alkyl group)optionally substituted by an aryl group.

Still further preferred for use in the invention are those compounds offormula I in which R¹ represents an alkyl group (e.g. C₁₋₂ alkyl,especially C₁ alkyl) substituted by an aryl group (e.g. phenyl).Preferred substituted alkyl R¹ groups which may be present in compoundsof formula I include C₁₋₆ alkyl, preferably C₁₋₄ alkyl, particularlypreferably C₁ or C₂ alkyl (e.g. C₁ alkyl) substituted (preferablyterminally substituted) by an optionally substituted aryl group.

By an “aryl group” is meant a group which is aromatic. Preferred arylgroups comprise up to 20 carbon atoms, more preferably up to 12 carbonatoms, for example, 10 or 6 carbon atoms.

Aryl groups which may be present in the compounds of the invention maybe heteroaromatic (e.g. 5-7 membered heteroaromatics) but are preferablynon-heteroaromatic. By “non-heteroaromatic” is meant an aryl grouphaving an aromatic system comprising electrons originating solely fromcarbon atoms. Preferred aryl groups include phenyl and napthyl,especially phenyl. In preferred compounds for use in the invention oneor two aryl groups may be present, preferably one.

Aryl groups which may be present in the compounds of the invention mayoptionally be substituted by one or more (e.g. 1 to 5), more preferablyone or two, groups (e.g. one group). Preferably the aryl group issubstituted at the meta or para position, most preferably the paraposition. Suitable substituent groups may include haloalkyl (e.g.trifluoromethyl), alkoxy (i.e. —OR groups wherein R is preferably a C₁₋₆alkyl group), halo (e.g. iodo, bromo, more especially chloro andfluoro), nitro and C₁₋₆ alkyl (preferably C₁₋₄ alkyl). Preferred C₁₋₆alkyl groups include methyl, isopropyl and t-butyl, particularly methyl.Particularly preferred substituent groups include chloro and nitro.Still more preferably the aryl group is unsubstituted.

In a further preferred aspect the invention provides the use of a photosensitiser which is a compound of formula I wherein R¹ represents anaryl substituted C₁₋₄ alkyl group (preferably C₁₋₂, e.g. C₁), preferablywherein said aryl group comprises up to 20 carbon atoms (e.g. up to 12carbon atoms, especially 6 carbon atoms) and is itself optionallysubstituted, and each R² is as hereinbefore defined (e.g. each R² ishydrogen), or a pharmaceutically acceptable salt thereof in themanufacture of a medicament for use in PDT.

Preferred compounds for use in the invention include methyl ALA ester,ethyl ALA ester, propyl ALA ester, butyl ALA ester, pentyl ALA ester,hexyl ALA ester, octyl ALA ester, 2-methoxyethyl ALA ester,2-methylpentyl ALA ester, 4-methylpentyl ALA ester, 1-ethylbutyl ALAester, 3,3-dimethyl-1-butyl ALA ester, benzyl ALA ester,4-isopropylbenzyl ALA ester, 4-methylbenzyl ALA ester, 2-methylbenzylALA ester, 3-methylbenzyl ALA ester, 4-[t-butyl]benzyl ALA ester,4-[trifluoromethyl]benzyl ALA ester, 4-methoxybenzyl ALA ester,3,4-[di-chloro]benzyl ALA ester, 4-chlorobenzyl ALA ester,4-fluorobenzyl ALA ester, 2-fluorobenzyl ALA ester, 3-fluorobenzyl ALAester, 2,3,4,5,6-pentafluorobenzyl ALA ester, 3-nitrobenzyl ALA ester,4-nitrobenzyl ALA ester, 2-phenylethyl ALA ester, 4-phenylbutyl ALAester, 3-pyridinyl-methyl ALA ester, 4-diphenyl-methyl ALA ester andbenzyl-5-[(1-acetyloxyethoxy)-carbonyl]amino levulinate.

Still further preferred compounds for use in the invention includemethyl ALA ester, ethyl ALA ester, 2-methoxyethyl ALA ester, benzyl ALAester, 4-isopropylbenzyl ALA ester, 4-methylbenzyl ALA ester,2-methylbenzyl ALA ester, 3-methylbenzyl ALA ester, 4-[t-butyl]benzylALA ester, 4-[trifluoromethyl]benzyl ALA ester, 4-methoxybenzyl ALAester, 3,4-[di-chloro]benzyl ALA ester, 4-chlorobenzyl ALA ester,4-fluorobenzyl ALA ester, 2-fluorobenzyl ALA ester, 3-fluorobenzyl ALAester, 2,3,4,5,6-pentafluorobenzyl ALA ester, 3-nitrobenzyl ALA ester,4-nitrobenzyl ALA ester, 2-phenylethyl ALA ester, 4-phenylbutyl ALAester, 3-pyridinyl-methyl ALA ester, 4-diphenyl-methyl ALA ester andbenzyl-5-[(1-acetyloxyethoxy)-carbonyl]amino levulinate

Particularly preferred compounds for use in the invention include methylALA ester, hexyl ALA ester and benzyl ALA ester, especially methyl ALAester.

The compounds for use in the invention may be prepared by anyconventional procedure available in the art (e.g. as described inWO02/10120 to PhotoCure ASA). For example, esters of 5-ALA may beprepared by reaction of 5-ALA with the appropriate alcohol in thepresence of acid. Alternatively compounds for use in the invention maybe available commercially (e.g. from Photocure ASA, Norway).

The compounds for use according to the invention may be in the form of afree amine (e.g. —NH₂, —NHR² or —NR²R²) or preferably in the form of aphysiologically acceptable salt. Such salts preferably are acid additionsalts with physiologically acceptable organic or inorganic acids.Suitable acids include, for example, hydrochloric, nitric, hydrobromic,phosphoric, sulphuric, sulphonic and sulphonic acid derivatives.Hydroiodic acids may also be suitable. Particularly preferred salts areacid addition salts with hydrochloric acid and sulphonic acidderivatives (e.g. mesylate or tosylate) as described in WO2005/092838 toPhotoCure ASA, the entire contents of which are incorporated herein byreference. Procedures for salt formation are conventional in the art.

In the uses and methods of the invention a single photosensitiser ashereinbefore defined (i.e. 5-ALA or a derivative of 5-ALA) may be usedalone in PDT. Alternatively, a combination of two or more, preferablytwo, photosensitisers may be used wherein at least one of thephotosensitisers is selected from 5-ALA and derivatives of 5-ALA, or apharmaceutically acceptable salt thereof.

Other photosensitisers which may be formulated with 5-ALA or aderivative of 5-ALA (e.g. a 5-ALA ester) or co-administered inaccordance with the invention include:

Hematoporphyrin derivative (HpD);

Hematoporphyrins such as Photofrin® (Quadra Logic Technologies Inc.,Vancouver, Canada) and Hematoporphyrin IX (HpIX);

Photosan III (Seehof Laboratorium GmbH, Seehof, Wesselburenerkoog,Germany);

Chlorins such as tetra(m-hydroxyphenyl)chlorins (m-THPC) and theirbacteriochlorins (Scotia Pharmaceuticals Ltd, Surrey, UK),mono-L-aspartyl chlorin e6 (NPe6) (Nippon Petrochemical Co., CA, USA),chlorin e6 (Porphyrin Products Inc.), benzoporphyrins (Quadra LogicTechnologies Inc., Vancouver, Canada) (e.g. benzoporphyrin derivativemonoacid ring A, BPD-MA) and purpurines (PDT Pharmaceuticals Inc., CA,USA) (e.g. tin-ethyl etiopurpurin, SnET2);

phthalocyanines (e.g. zinc-(Quadra Logic Technologies Inc., Vancouver,Canada), some aluminium- or silicon phthalocyanines, which may besulfonated, in particular sulfonated phthalocyanines such as aluminiumphthalocyanine di-sulfonate (A1PcS_(2a)) or aluminium phthalocyaninetetra-sulfonate (Al PcS₄));

porphycenes;

hypocrellins;

Protoporphyrin IX (PpIX);

Hematoporphyrin di-ethers;

Uroporphyrins;

Coproporphyrins;

Deuteroporphyrin;

Polyhematoporphyrin (PHP), and precursors and derivatives thereof; and

antibiotics such as tetracycline (e.g. Topicycline®, Shire).

Preferably the second photosensitiser will be a Hematoporphyrin (e.g.Photofrin®), a chlorin (particularly m-THPC or chlorin e6) or asulphonated phthalocyanine (particularly aluminium phthalocyaninedi-sulfonate or aluminium phthalocyanine tetra-sulfonate).

If a second photosensitiser is used together with 5-ALA or 5-ALAderivatives according to the uses and methods of the present invention,the PDT conditions still preferably ensure that few, if any, sideeffects of treatment occur. This may be achieved by use of at least oneof (i)-(iv) as hereinbefore described and optionally a low dose (e.g.sub-therapeutic dose) of the second photosensitiser.

Thus in a further aspect the invention provides the use of a firstphotosensitiser which is 5-ALA or a derivative of 5-ALA as hereinbeforedefined, or a pharmaceutically acceptable salt thereof, together with asecond photosensitiser in the manufacture of a composition for use inPDT as hereinbefore defined.

Furthermore the compounds for use according to the invention may beformulated and/or administered with other active components which areable to increase the photosensitizing effect and thus enhance the PDT.For example, chelating agents may beneficially be included and/orco-administered in order to enhance the accumulation of Pp; thechelation of iron by the chelating agent prevents its incorporation intoPp to form haem by the action of the enzyme ferrochelatase, therebyleading to a build-up of Pp. The photosensitizing effect is thusenhanced.

Suitable chelating agents include aminopolycarboxylic acids, includingany of the chelants described in the literature for metal detoxificationor for the chelation of paramagnetic metal ions in magnetic resonanceimaging contrast agents. Particular mention maybe made of EDTA, CDTA(cyclohexane diamine tetraacetic acid), DTPA and DOTA and well knownderivatives/analogues thereof EDTA and DTPA are particularly preferred.To achieve the iron-chelating effect, desferrioxamine and othersiderophores may also be used, e.g. in conjunction withaminopolycarboxylic acid chelating agents such as EDTA.

Where present, the chelating agent may conveniently be used at aconcentration of 0.05 to 20%, e.g. 0.1 to 10% (w/w).

Penetration enhancers may also have a beneficial effect in enhancing thephotosensitizing effect of the compounds for use in the invention.Surface-penetration assisting agents, especially dialkylsuphoxides suchas dimethylsulphoxide (DMSO), may therefore also be included in thecompositions for use in the invention and/or co-administered. Thesurface-penetration assisting agent may be any of the skin-penetrationassisting agents described in the pharmaceutical literature e.g.chelators (e.g. EDTA), surfactants (e.g. sodium dodecyl sulphate),non-surfactants, bile salts (e.g. sodium deoxycholate) and fatty acids(e.g. oleic acid). Examples of appropriate surface penetrating assistingagents include isopropanol, HPE-101 (available from Hisamitsu), DMSO andother dialkylsulphoxides, in particular n-decylmethyl-sulphoxide (NDMS),dimethylsulphacetamide, dimethylformamide (DMFA), dimethylacetamide,glycols, various pyrrolidone derivatives (Woodford et al., J. Toxicol.Cut. & Ocular Toxicology, 1986, 5: 167-177), and Azone® (Stoughton etal., Drug Dpv. Ind. Pharm. 1983, 9: 725-744), or mixtures thereof.

The surface penetration agent may conveniently be provided in aconcentration range of 0.2 to 50% (w/w), e.g. about 10% (w/w).

The compositions for use in accordance with the invention mayadditionally include lubricating agents, wetting agents, emulsifyingagents, suspending agents, preserving agents, sweetening agents,flavouring agents, adsorption enhancers, e.g. surface penetrating agentsas mentioned below, and the like.

The compounds for use according to the invention may be formulated inany conventional manner with one or more physiologically acceptablecarriers or excipients, according to techniques well known in the art.Where appropriate, compounds or compositions for use in the inventionare sterilized, e.g. by γ-irradiation, autoclaving or heatsterilization, before or after the addition of a carrier or excipientwhere that is present, to provide sterile formulations. The compositionsof the invention may also be formulated so as to provide quick,sustained or delayed release of the active ingredient afteradministration to the patient by employing procedures well known in theart. Solubilizing and/or stabilizing agents may, for example, be used,e.g. cyclodextrins (CD) α, β, γ and HP-β cyclodextrin. Compositions maybe in any appropriate dosage form, for example as an emulsion or inliposomes, niosomes, microspheres, nanoparticles or the like. Thecompounds for use in the invention may then be absorbed to, incorporatedin or bound to these forms.

The pH in the final composition is preferably in the range 2.5 to 7.4.Slightly acidic pH, for example pH 5-7, is preferred.

Compositions may be administered systemically (e.g. orally orparenterally) or more preferably locally (e.g. by injection ortopically) at or near the affected site. The route of administrationwill depend on the severity, nature and location of the disease to betreated as well as the photosensitiser (or combination ofphotosensitisers) used. Generally, however, local administration, stillmore preferably, topical application is preferred. Topicaladministration to inaccessible sites may be achieved by techniques knownin the art, e.g. by the use of catheters or other appropriate drugdelivery systems.

Compositions that may be administered systemically include plain orcoated tablets, capsules, suspensions and solutions containing theactive component optionally together with one or more inert conventionalcarriers and/or diluents, e.g. with corn starch, lactose, sucrose,microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone,citric acid, tartaric acid, water, water/ethanol, water/glycerol,water/sorbitol, water/polyethyleneglycol, propyleneglycol,stearylalcohol, carboxymethylcellulose or fatty substances such as hardfat or suitable mixtures thereof.

Compositions that may be administered locally (e.g. topically) includegels, creams, ointments, sprays, lotions, salves, sticks, soaps,powders, pessaries, aerosols, drops, solutions and any of the otherconventional pharmaceutical forms in the art. Creams, ointments and gelsare especially preferred.

Creams, ointments and gels may be formulated with an aqueous or oilybase with the addition of suitable thickening and/or gelling agents.Lotions may be formulated with an aqueous or oily base and will, ingeneral, also contain one or more emulsifying, dispersing, suspending,thickening or colouring agents. Powders may be formed with the aid ofany suitable powder base. Drops and solutions may be formulated with anaqueous or non-aqueous base also comprising one or more dispersing,solubilising or suspending agents. Aerosol sprays are convenientlydelivered from pressurised packs, with the use of a suitable propellant.

Particularly preferably the compositions for use in PDT according to theinvention will be in the form of a ready-to-use composition such as acream or as a kit as hereinbefore defined.

The concentration of the 5-ALA compounds described herein in the finalcompositions for PDT will vary depending on several factors includingthe chemical nature of the compound, the chemical composition, mode ofadministration and nature of the disease to be treated. Preferably,however, concentration ranges of less than 20% wt, more preferably lessthan 10% wt, still more preferably 0.05 to 8% wt, yet more preferably0.5 to 6% wt, e.g. 1.5 to 4.5% wt or 2 to 4% wt are used. The mostpreferred concentrations for local (e.g. topical) administration is inthe range 2 to 4% wt.

Thus viewed from a yet further aspect the invention provides apharmaceutical composition comprising a photosensitiser which is 5-ALAor a derivative of 5-ALA as hereinbefore defined and a pharmaceuticallyacceptable carrier or excipient, wherein the concentration of saidphotosensitiser is 2 to 8% wt (e.g. 2 to 4.5% wt).

Viewed from a still further aspect the invention provides apharmaceutical composition comprising a photosensitiser which is 5-ALAor a derivative of 5-ALA as hereinbefore defined and a pharmaceuticallyacceptable carrier or excipient, wherein the concentration of saidphotosensitiser is 2 to 8% wt (e.g. 2 to 4.5% wt) for use in therapy(e.g. PDT).

Viewed from a still further aspect the invention provides a product orkit for use in a method of preventing or reducing side-effects (e.g.pain and/or erythema) of photodynamic therapy (PDT) in an animalcomprising:

-   -   (a) a container containing a composition as hereinbefore defined        (e.g. a composition comprising a photosensitiser which is 5-ALA        or a derivative of 5-ALA at a concentration of less than 20% wt,        e.g. less than 10% wt), and    -   (b) instructions for carrying out said PDT as herein defined.

In particularly preferred products and kits, the composition containedin the first container comprises the composition which itself forms anaspect of the invention (i.e. a composition comprising a photosensitiserwhich is 5-ALA or a derivative of 5-ALA as hereinbefore defined in aconcentration of 2 to 8% wt (e.g. 2 to 4.5 wt %)). Further preferredproducts and kits comprise a second container containing a secondphotosensitiser, e.g. as hereinbefore defined.

The instructions present in the products and kits of the inventiondescribe the steps of administering the composition comprising aphotosensitiser to an animal and photoactivating the photosensitiser.The instructions also preferably describe at least one of steps (ii),(iii) or (iv) as herein defined.

PDT is carried out by administering to an animal a compositioncomprising a photosensitiser as hereinbefore defined and photoactivatingthe photosensitiser. By use of at least one of (i)-(iv) as hereinbeforedefined the side effects of PDT are prevented or reduced. By “sideeffects” is meant herein effects, usually undesirable effects, caused byPDT, other than its desired therapeutic effect. Representative examplesof side effects commonly associated with PDT include pain, erythema,swelling, edema, burning, itching, exfoliation, hyperpigmentation andprolonged irritation and hypersensitivity after treatment. The uses andmethods of the present invention are particularly useful for preventingor reducing pain and/or erythema, especially pain.

In particularly preferred uses and methods of the invention, the PDT hassubstantially the same therapeutic effect as the corresponding standardPDT treatment, whilst preventing or reducing the side effects of thestandard treatment. By the term “corresponding standard PDT treatment”is meant the PDT treatment carried out with the same photosensitiser(e.g. the same 5-ALA ester) and the same light dose (e.g. 37 J/cm²), butunder the following conditions:

-   -   (I) the concentration of the photosensitiser is at least 15% wt        (e.g. 16% wt),    -   (II) the photosensitiser is administered for at least 3 hours        (e.g. 3 hours) prior to photoactivation; and    -   (III) photoactivation is carried out with a light source having        a fluence rate of at least 60 mW/cm², e.g. about 70 mW/cm².

Particularly preferred uses and methods of the invention provide atleast 90%, still more preferably at least 95%, e.g. at least 99% of thetherapeutic effect of the corresponding standard PDT treatment.

In preferred uses and methods of the invention, side effects of PDT areprevented or reduced by use of (i) as hereinbefore described, i.e. useof a composition comprising the photosensitiser in a concentration ofless than 10% wt (e.g. 0.5 to 8% wt). Particularly preferredcompositions comprise photosensitiser in a concentration of 0.05 to 8%wt, still more preferably 0.5 to 6% wt, e.g. 1 to 4.5% wt or 2 to 4% wt.

In further preferred uses and methods of the invention, the compositioncomprising the photosensitiser(s) as hereinbefore described isadministered to the animal and a certain time period is allowed toelapse before the site to be treated is exposed to light to achieve thedesired photosensitizing effect. By the term “administered” is meantthat the composition is delivered to the animal. This may be achieved,for example, by applying the composition to the skin and allowing it topermeate therethrough. Preferably the composition is administered in asingle application. Before light exposure, excess photosensitiser ispreferably removed.

The length of time following administration at which light exposuretakes place will depend on the nature of the composition, the conditionto be treated and the form of administration. It may be, for example,about 3 to 6 hours. In preferred uses and methods of the invention,however, side effects of PDT are prevented or reduced by use of (ii) ashereinbefore defined, i.e. by administering the composition for lessthan 2 hours prior to photoactivation. Still more preferably thecomposition is administered for 0 to 90 minutes (e.g. 5 to 90 minutes,preferably 30 to 90 minutes), more preferably 10 to 50 minutes, stillmore preferably 15 to 45 minutes, e.g. 20 to 40 minutes prior tophotoactivation. In a particularly preferred aspect of the invention,light exposure maybe effected immediately after administration of thephotosensitiser, i.e. the period of administration may be a matter ofonly minutes (e.g. up to 10 minutes, more preferably up to 5 minutes) ormay effectively be zero in the case where administration andphotoactivation occur simultaneously.

In the uses and methods of the invention, photoactivation may beachieved using light sources known in the art. Methods for theirradiation of different areas of the body, e.g. by lamps or lasers arewell known in the art (see for example Van den Bergh, Chemistry inBritain, May 1986 p. 430-439). The wavelength of light used forirradiation may be selected to achieve a more efficaciousphotosensitizing effect. The most effective light is light in thewavelength range 300-800 nm, typically 400-700 nm. The irradiation willin general be applied at a dose level of 40 to 200 Joules/cm², forexample at 100 Joules/cm². A light source having a fluence rate of 60 to100 mW/cm² maybe used.

In particularly preferred uses and methods of the invention, sideeffects of PDT are prevented or reduced by use of (iii) as hereinbeforedescribed, i.e. by photoactivating with a light source having a fluencerate of less than 50 mW/cm². Still more preferably photoactivation iscarried out with a light source having a fluence rate of 5 to 40 mW/cm²,still more preferably 10 to 35 mW/cm², e.g. 15 to 35 mW/cm².

Still more preferably the irradiation is applied at a dose of 10 to 100J/cm², more preferably 20 to 60 J/cm², e.g. about 37 Joules/cm² .Penetration of light into tissues depends on the wavelength used and isdeeper for red light than for blue light. Irradiation is preferablyperformed for 5 to 30 minutes, preferably for 15 minutes, depending onthe light dose and fluence rate. A single irradiation may be used oralternatively a light split dose in which the light dose is delivered ina number of fractions, e.g. a 1 to 10 minutes between irradiations, maybe used.

In further preferred uses and methods of the invention, side effects ofPDT are prevented or reduced by use of (iv) as hereinbefore defined,i.e. by photoactivating with sunlight. This aspect of the inventionincludes photoactivation with either natural sunlight or any lightsource which provides artificial sunlight (i.e. the entire range from UVto IR). Use of natural sunlight as the light source has the advantagethat the animal being treated is free to leave the clinical environmentwhere treatment is normally conducted. Furthermore, as the intensity ofsunlight (whether natural or artificial) is so low, exposure cancommence as soon as administration begins (i.e. the administration timemay effectively be zero). Thus, in a preferred aspect of the invention,photoactivation by sunlight may be effected immediately followingadministration of the photo sensitiser. This is a particularly preferredform of treatment for skin disorders, e.g. in the treatment of acne.Moreover, it may also not be necessary to remove excess photosensitiserprior to photoactivation using sunlight therefore administration andphotoactivation can be carried out at the same time. Indeed, it may inmany cases be beneficial to retain excess photosensitiser at the site ofadministration such that administration essentially continues duringphotosensitisation. Since the intensity of natural sunlight may varyduring the illumination period, if necessary, the light dose received bya subject from sunlight can easily be monitored by way of a portablephotometer. Such photometers are commercially available fromInternational Light Technologies. These monitor the total light dose andgive a signal to the patient when the desired light dose has beenreached.

The desired period of exposure to sunlight following administration ofthe photosensitiser will depend on various factors such as the nature ofthe composition, the condition to be treated, the form ofadministration, etc. but may readily be determined by those skilled inthe art. It has, however, been found that the pain associated with PDTis less during the first 3 hours or so of exposure to sunlight and thatthis is sufficient for the desired therapeutic effects to be achieved.In a preferred aspect of the invention the period of exposure tosunlight may therefore be in the range of from 2 to 4 hours, e.g. about3 hours.

In particularly preferred uses and methods of the invention, sideeffects of PDT are prevented or reduced by use of (i) as hereinbeforedefined in combination with at least one of (ii), (iii) and (iv).Prevention or reduction of side effects by use of (i) in combinationwith (ii) or (iii), especially (ii), is particularly preferred.

In other particularly preferred uses and methods of the invention, sideeffects of PDT are prevented or reduced by use of (ii) as hereinbeforedefined in combination with at least one of (iii) and (iv). Preventionor reduction of side effects by use of (ii) in combination with (iv) isparticularly preferred. In these uses and methods, the photosensitiseris preferably administered for 15 to 45 minutes (e.g. for 30 minutes)prior to photoactivation. Preferably excess photosensitiser is notremoved prior to photoactivation so administration may continue duringthe activation.

In further particularly preferred uses and methods of the invention,side effects of PDT are prevented or reduced by use of at least (i),(ii) and (iii) or (i), (ii) and (iv), e.g. (i), (ii) and (iii).

In yet further preferred embodiments of the invention, side-effects ofPDT are prevented or reduced by use of (iii) in combination with (i)and/or (ii), e.g. by use of (iii) and (i); (iii) and (ii); or (iii) and(i) and (ii).

In other yet further preferred embodiments of the invention,side-effects of PDT are prevented or reduced by use of (iv) incombination with (i) and/or (ii), e.g. by use of (iv) and (i); (iv) and(ii); or (iv) and (i) and (ii).

In the methods and uses of the present invention, multiple treatmentsmay be given, e.g. daily, weekly or monthly treatment. Preferably nomore than two treatments are required, e.g. for PDT of acne.

The methods and uses of the invention may be used to treat any diseaseknown to be treatable by PDT. Examples of diseases which may be treatedinclude any malignant, pre-malignant and non-malignant abnormalities ordisorders responsive to photochemotherapy e.g. cancers (e.g. basal cellcarcinoma (bcc), tumours, squamous cell carcinoma (scc), Bowen'sdisease), skin disorders (e.g. psoriasis, actinic keratoses and acne)and infections (e.g. bacterial, viral or fungal infections, for exampleHerpes virus infections). The invention is particularly suited to thetreatment of diseases, disorders or abnormalities where discrete lesionsare formed to which the compositions may be directly applied (lesions isused here in a broad sense to include tumours and the like).

In some embodiments the uses and methods of the present invention areparticularly suited to the treatment of diseases other than acne.

The internal and external body surfaces which may be treated accordingto the invention include the skin and all other epithelial and serosalsurfaces, including for example mucosa, the linings of organs e.g. therespiratory, gastro-intestinal and genito-urinary tracts, and glandswith ducts which empty onto such surfaces (e.g. liver, hair follicleswith sebaceous glands, mammary glands, salivary glands and seminalvesicles). In addition to the skin, such surfaces include for examplethe lining of the vagina, the endometrium and the urothelium. Suchsurfaces may also include cavities formed in the body following excisionof diseased or cancerous tissue e.g. brain cavities following theexcision of tumours such as gliomas.

Exemplary surfaces thus include: (I) skin and conjunctiva; (2) thelining of the mouth, pharynx, oesophagus, stomach, intestines andintestinal appendages, rectum, and anal canal; (3) the lining of thenasal passages, nasal sinuses, nasopharynx, trachea, bronchi, andbronchioles; (4) the lining of the ureters, urinary bladder, andurethra; (5) the lining of the vagina, uterine cervix, and uterus; (6)the parietal and visceral pleura; (7) the lining of the peritoneal andpelvic cavities, and the surface of the organs contained within thosecavities; (8) the dura mater and meninges; (9) any tumors in solidtissues that can be made accessible to photoactivating light e.g. eitherdirectly, at time of surgery, or via an optical fibre inserted through aneedle.

The uses and methods of the invention are particularly suited, however,to the PDT treatment of diseases of the face, scalp or neck, especiallythe face.

The uses and methods of the present invention are particularly suited tothe treatment of acne. As used herein, the term “acne” includes bothinflammatory and non-inflammatory diseases of the pilosebaceous unit.Primarily, however, the uses and methods herein described will be usedfor treating inflammatory types of acne where bacterial invasion of thepilosebaceous unit or follicles has occurred. The compounds describedherein are preferably used for the treatment or prevention (preferablyfor the treatment) of acne associated with Propionibacterium bacteria(e.g. P. acnes, P. granulosum and P. avidum); especiallyPropionibacterium acnes.

Acne is categorised into different forms depending, for example, on thenature, severity and/or location of the blackheads, whiteheads, papules,pustules and/or cysts. Representative types of acne which may be treatedaccording to the invention include acne vulgaris, acne rosacea, acneconglobate, acne papulosa and premenstrual acne, preferably acnevulgaris which is a chronic inflammatory disease of the pilosebaceousapparatus. Acne may occur on the back, chest, upper arms and/or face;the compounds described herein may be used for treating any of theseareas of the body, especially the face.

The uses and methods of the present invention are also particularlysuited to the treatment of cancers. Representative examples of cancersthat may be treated include bcc, tumors, scc and Bowen's disease.

The invention will now be described in more detail by way of thefollowing non-limiting Examples.

EXAMPLES Example 1

A clinical Phase II study involving 23 males and 20 females (age 18years or more) with facial acne vulgaris (papulo-pustular acne and atleast 15 inflammatory, acne lesions on at least one side of the face)has been performed.

This study assessed porphyrin levels, safety and efficacy of PDTperformed after application of three different concentrations ofmethylaminolevulinate (MAL) in a cream base. It further assessed theeffect of different time intervals between MAL application and lightexposure.

Patients were randomized to receive either MAL cream on the face at aconcentration of 160 mg/g (16% wt), 80 mg/g (8% wt)or 40 mg/g (4% wt).Patients had skin biopsies taken on one half of the face (each patienthad a total of two biopsies taken) and the other half of the face wasexposed to red light (37 J/cm² using Photocure's Aktilite 128 LED lightsource) as indicated in the table below.

Half of face Other half of face Concentration of MAL Skin biopsiestaken* Illumination performed* in cream (hrs) (hrs) 160 mg/g^(#) 0, 3 380 mg/g 0, 0.5, 1, 1.5 0.5, 1, 1.5 40 mg/g 0, 1, 1.5 1, 1.5 *Creamapplied at 0 hrs. ^(#)Standard PDT treatment

Acne lesion counts (inflammatory and non inflammatory lesions for thehalf face exposed to red light) was performed at 0 hours as well as atday 14 and day 84 visits by a blinded evaluator. A Global Acne SeverityAssessment was also performed at day 0, day 14 and day 84.

In vivo fluorescence spectroscopy was performed at 0 hours andimmediately after red light exposure to measure porphyrin photobleachingafter illumination. Sebum excretion rates were measured 7 days beforeday 0, at day 14 and day 84.

Safety was evaluated by medical questionnaire and adverse eventsreporting.

This study showed a significant difference between treatment groups inporphyrins levels after MAL application as measured with in vivofluorescence spectroscopy. Porphrin levels were highest in facial skinof acne patients treated with MAL at 160mg/g for 3 hours and 80 mg/g for1.5 hours. These elevated levels went back to baseline levels after redlight exposure.

Mean porphyrin levels were highest in sebaceous glands from biopsiestaken 3 hours after application of 160 mg/g but there was no significantdifference between treatment groups in mean porphyrin levels insebaceous glands.

Surprisingly there was no difference between MAL-PDT treatment groups ininflammatory or non-inflammatory lesions at either day 14 or day 84.However a reduction from the start of the study in inflammatory lesions(between 23% to 44% at Day 84) was noted for all groups on the MAL-PDTtreated side. There was no difference between treatment groups in Globalacne severity scores or sebum excretion rates at day 14 and day 84 thusshowing that all treatment regimes were equally efficient.

Mean pain during light exposure was evaluated by patients on a visualanalog scale where 0=no pain, 50=moderate pain and 100=worst possiblepain. The results are shown in the Table below.

Pain during light exposure Treatment N Mean Std Dev 1 h after MAL (40mg/g) 8 2 4 1.5 h after MAL (40 mg/g) 8 19 19 0.5 h after MAL (80 mg/g)6 1 1 1 h after MAL (80 mg/g) 8 9 16 1.5 h after MAL (80 mg/g) 6 32 32 3h after MAL (160 mg/g)# 7 64 13 #Standard PDT treatment

There was a statistically significant difference between groups in meanpain during light exposure (p=0.0006). Pairwise comparison between the160 mg/g 3 h group and all other groups showed a higher mean pain duringlight exposure for the 160 mg/g group except for the comparison with the80 mg/g 1.5 h group which was at the limit of significance (p=0.06). Infact, for a few patients in these two groups the pain was so strong thatthe light delivery had to be interrupted (2 patients) or ended (2patients). This shows that pain is related to exposure time and MALconcentration.

The duration of post-PDT erythema is presented in the Table below. Thisinformation was derived from the journal kept by patients. The longestmean duration of erythema (14 days) was seen in patients treated with160 mg/g for 3 hours and the shortest (0.5 days) was seen in patientstreated with 40 mg/g for 1 hour. There is a significant difference amongthe 6 groups in the duration of post PDT erythema (p=0.03).

Duration of post PDT erythema (in days) Treatment n Mean Std Dev 1 hafter MAL (40 mg/g) 4 4 6.7 1.5 h after MAL (40 mg/g) 6 1.8 1.3 0.5 hafter MAL (80 mg/g) 0 — — 1 h after MAL (80 mg/g) 5 2.1 2.7 1.5 h afterMAL (80 mg/g) 3 3.7 0.6 3 h after MAL (160 mg/g)# 7 11.9 11.7 #StandardPDT treatment

This shows that post-PDT erythema is related to exposure time and MALconcentration.

The study shows that there was no significant difference in thetherapeutic effect between groups, but there was a significantdifference between groups for the duration of post-PDT erythema, localtolerance to PDT and pain during light exposure which was longest,lowest and highest respectively in the 160 mg/g 3 h group.

Example 2

A study was performed to evaluate the effect of reducing the fluencerate during illumination.

34 patients with moderate to severe facial acne vulgaris were treatedfull-face with Metvix® (160 mg/g) applied for three hours underocclusion. The cream was removed, and the treatment area was illuminatedwith a total light dose of 37 J/cm² using the Aktilite® 128 lamp(Photocure ASA, Norway). This lamp consists of 128 light emitting diodes(LEDs) and has a peak wavelength of 634±3 nm.

15 patients had one PDT treatment with no curettage prior to Metvix®application and using a fluence rate of 34 mW/cm². The remaining 19 acnepatients were supposed to have 2 PDT treatments and were illuminatedwith a fluence rate of 68 mW/cm² and curettaged before the firsttreatment. 12 of these patients had 2 PDT treatments and 7 patients onlyone treatment.

The treatment effect was evaluated as reduction in number ofinflammatory acne lesions from baseline to 12-week control. Pain duringillumination was assessed using a numerical scale ranging from 0 to 10in which 0 is no pain and 10 is worst imaginable pain.

The results are summarised in the table below:

Reduction inflammatory FLUENCE Number of acne lesions RATE patientsMedian percentage P value 68.5 mW/cm² 19 70% 0.92   34 mW/cm² 15 59%

It is evident from the table that there was no significant differencebetween the two groups with respect to treatment effect.

FLUENCE Number of Maximal Pain P *Corrected RATE treatment sessionsMedian (IQR) value P value 68.5 mW/cm² 31 8 (6, 10) 0.018 0.009   34mW/cm² 15 6 (5, 7)  *By correcting the pain scores for differences inporphyrin fluorescence (measured by quantitative fluorescence imaging)in the treatment area, we take into account differences in curettage andtreatment number between the two treatment groups.

Example 3

A study was performed to demonstrate that illumination with sunlight isas effective as if a PDT lamp was used.

Patients with actinic keratosis (23 men and 6 women) median age 80 years(63-93 years) were included in this study.

A gentle curettage was performed followed by application of Metvix®cream (160 mg/g). The treated area was then occluded. After 30 minutesthe occlusion was removed on half the treatment area, which was thenexposed to sunlight for 2.5 hours.

The occlusion was then removed on other half followed by illuminationusing the Aktilite® 128 lamp (Photocure ASA, Norway)—for details seeExample 2. Photodynamic treatment was performed with a total light doseof 37 Joules/cm² and a fluence rate of 68.5 mW/cm².

Sunlight exposure LUX* No. of patients Mean LUX >80,000 14 92,36250,000-80,000 9 68,277 <50,000 6 38,296 *1 LUX = 1 lumen/m²

The treatment effect was scored by lesion counting before treatment and12 weeks after the PDT treatment:

Treatment effect SUNLIGHT RED LIGHT Median Median p (range) (range)value* Number of lesions 9 (2-27) 9 (1-32) 0.76 before treatment Numberof lesions at 2 (0-8)  3 (0-9)  0.35 12 week follow up Absolute decrease7 (1-22) 6 (0-27) 0.58 (number of lesions) Lesions with complete  81(43-100) 75 (0-100) 0.19 response (percent) *Sunlight group vs. redlight group

Pain was scored using a numerical scale ranging from 0 to 10 in which 0is no pain and 10 is worst imaginable pain.

Pain Maximal pain Light exposure Median (range) p value Sunlight 2(0-6)  <0.0001 Red light 7 (2-10)

It is evident from the table that there was no significant differencebetween the two illumination groups with respect to the absolutedecrease in number of lesions or in the percentage of lesions with acomplete response. It can therefore be concluded that exposure ofcontinuously formed protoporphyrin to sunlight during 2.5 hourstreatment with Metvix® is as efficient as illumination with red lightafter 3 hours of incubation with Metvix®.

Pain during light exposure was significantly lower in the sunlightgroup. There was no significant correlation between intensity of thesunlight exposure and the reduction in lesions in the area treated withMetvix® and sunlight (p=0.66). Neither was there any significantcorrelation between intensity of the sunlight exposure and pain duringexposure (p=0.1036).

1.-44. (canceled)
 45. A method of reducing or preventing side-effects inthe photodynamic treatment of acne comprising: (a) administering to anarea characterized by acne on a patient in need of such treatment acomposition comprising methyl ALA ester at a concentration of less than10%, or the equivalent concentration of a pharmaceutically acceptablesalt, for a period of less than 2 hours, and (b) administeringphotoactivating light to the affected area.
 46. The method of claim 45,wherein the administered compound is methyl ALA ester hydrochloridesalt.
 47. The method of claim 45, wherein the concentration of methylALA ester is in the range from 0.5 to 8%, or the equivalentconcentration of a pharmaceutically acceptable salt.
 48. The method ofclaim 47, wherein the concentration of methyl ALA ester is in the rangefrom 2 to 8%, or the equivalent concentration of a pharmaceuticallyacceptable salt.
 49. The method of claim 48, wherein the concentrationof methyl ALA ester is 8%, or the equivalent concentration of apharmaceutically acceptable salt.
 50. The method of claim 45, whereinthe administered compound is methyl ALA ester hydrochloride salt. 51.The method of claim 45, wherein the composition is a cream.
 52. Themethod of claim 45, wherein the composition is administered for a periodof 5 to 90 minutes.
 53. The method of claim 52, wherein the compositionis administered for a period of 30 to 90 minutes.
 54. The method ofclaim 53, wherein the composition is administered for a period of 90minutes.
 55. The method of claim 45, wherein the photoactivating lighthas a peak wavelength in the range 631 to 637 nm.
 56. The method ofclaim 45, wherein the total light dosage is about 37 J/cm².
 57. Themethod of claim 45, wherein the photoactivating light has a fluence rateof about 21 to about 74 mW/cm².
 58. The method of claim 45, wherein thelight is provided by an LED lamp.